Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.52)
# 207
Out of 5,127 analysts
118
Total ratings
52.78%
Success rate
24.71%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Reiterates: Buy | $5 | $0.33 | +1,415.15% | 8 | Jan 2, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.49 | +302.68% | 3 | Dec 2, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $26.62 | -2.33% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.66 | +1,107.18% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $33.13 | +69.03% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $15.60 | +66.67% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $16.41 | +168.13% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $78.21 | +12.52% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.35 | +43.71% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $3.80 | +321.05% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $15.24 | +267.45% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.00 | +300.00% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $7.00 | +42.86% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.18 | +139.23% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $19.06 | +67.89% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $7.30 | +393.15% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $442.94 | -93.68% | 1 | Aug 22, 2023 |
FibroBiologics
Jan 2, 2026
Reiterates: Buy
Price Target: $5
Current: $0.33
Upside: +1,415.15%
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.49
Upside: +302.68%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $26.62
Upside: -2.33%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.66
Upside: +1,107.18%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $33.13
Upside: +69.03%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $15.60
Upside: +66.67%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $16.41
Upside: +168.13%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $78.21
Upside: +12.52%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.35
Upside: +43.71%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $3.80
Upside: +321.05%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $15.24
Upside: +267.45%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $7.00
Upside: +42.86%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.18
Upside: +139.23%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $19.06
Upside: +67.89%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $7.30
Upside: +393.15%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $442.94
Upside: -93.68%